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Abstract 
BACKGROUND & AIMS: The non-invasive identification of steatohepatitis (NASH) in patients 
with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH 
(ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to 
compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in 
combination with non-invasive tools for fibrosis.  
METHODS: We analyzed data from 292 Italian patients (169 Southern cohort, and 123 Northern 
cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated 
according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness 
(LS) by Fibroscan were assessed within three months from liver biopsy.  
RESULTS: The diagnostic accuracy of ION for the identification of NASH was not as satisfactory 
as reported (area under the ROC curve, AUROC=0.687 [95% CI = 0.62-0.75]). The proposed cut-
off value ≥50 showed a poor sensitivity (Se) (28%) and a good specificity (Sp) (92%), with a 
positive predictive value (PPV) of 91% and a negative predictive value (NPV) of 30%. A new cut-
off value >26 improved Se (73%) but decreased Sp (60%) (PPV of 84% and a NPV of 43%). ION 
performed slightly better in obese NAFLD (AUROC= 0.700). The combination of ION and markers 
of fibrosis did not improve the identification of advanced liver disease.  
CONCLUSIONS: ION is not feasible for the non-invasive diagnosis of NASH across different 
populations of NAFLD patients, mainly because its limited reproducibility in non-obese subjects.  
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WHAT IS CURRENT KNOWLEDGE 
• The non-invasive diagnosis of nonalcoholic steatohepatitis (NASH) in patients with 
nonalcoholic fatty liver disease (NAFLD) is one of the most important unmet needs in 
clinical practice. 
• A new non-invasive algorithm for the prediction of NASH, the ION index, has been recently 
developed, showing a good diagnostic accuracy in a population of obese NAFLD subjects. 
 
WHAT IS NEW HERE 
• ION is not feasible for the non-invasive diagnosis of NASH across different populations of 
NAFLD patients, mainly because its limited reproducibility in non-obese subjects.  
• The combination of ION with a marker of fibrosis does not improve the diagnostic 
performance of the tools for the non-invasive exclusion of severe fibrosis. 
 
Introduction 
Nonalcoholic fatty liver disease (NAFLD), traditionally considered as the hepatic manifestation of 
the metabolic syndrome (MetS), is rapidly becoming the most common chronic hepatitis in Western 
countries (1,2) in parallel with the pandemic of obesity and Type 2 Diabetes (T2DM). 
NAFLD is a slowly progressive disease, but in clinical practice the early recognition of its 
potentially progressive phenotype, nonalcoholic steatohepatitis (NASH), as well as the 
identification of fibrosis, is still elusive (3). Overall, a fair accuracy has been reached in excluding 
severe (F3/F4) fibrosis by non-invasive markers derived from algorithms such as FIB-4 and 
NAFLD fibrosis score (NFS) (4-8), or by Liver Stiffness (LS) (9-14), currently suggested as 
screening tools by the new EASL-EASO-EASD clinical practice guidelines (2). Nevertheless, 
despite the large effort of the scientific community, to date liver biopsy remains the only procedure 
able to identify NASH (15-17), but its use for large-scale diagnosis is impracticable. Cytokeratin-18 
fragments (CK-18), which are generated during cell death (M65fragments) or apoptosis (M30 
fragments), have a modest accuracy as marker of NASH (18,19). Recently Otgonsuren et al (20) 
have developed a new algorithm based on the combination of visceral obesity, triglycerides, ALT 
and HOMA-IR, the index of NASH (ION), able to identify NASH with a good diagnostic accuracy 
(AUC = 0.88 [95%CI 0.82–0.95]) in a validation cohort with biopsy-proven NAFLD.  
The first aims of our study was the external validation of the diagnostic accuracy of the ION index 
in a cohort of patients with biopsy-proven NAFLD and the comparison of its diagnostic 
performance with CK-18. Secondly, since the histological features of NASH are often associated 
with fibrosis or can predict its development, we tested the performance of ION and CK-18 as 
markers of fibrosis in comparison or in combination with the non-invasive tools currently 
recommended by guidelines, i.e. FIB-4, NFS and LS.  
 
Material and Methods.  
Study population 
The study cohort includes a total of 292 Caucasian patients with biopsy proven NAFLD 
prospectively enrolled in the Division of Gastroenterology of the Torino University Hospital 
(Northern cohort, N=123) and in the Gastrointestinal and Liver Unit of the Palermo University 
Hospital (Southern cohort, N=169). The liver biopsy was performed to confirm the diagnosis of 
NAFLD in patients with features of MetS and ultrasound finding of fatty liver or persistent (> 6 
months) elevation of ALT or AST after exclusion of liver disease of other etiology, such as alcohol-
induced or drug-induced liver disease, autoimmune or viral hepatitis, and cholestatic or genetic liver 
disease. All patients had current and past consumption of ethanol less than 20 g per day on direct 
questioning of both the patients and a close relative. The final diagnosis was based on a liver biopsy 
showing features consistent with NAFLD.  
The study was approved by the ethics committees of the University Hospitals of Torino and 
Palermo in accordance with the Helsinki Declaration and an informed consent has been obtained by 
all patients. 
 
Clinical, anthropometric and laboratory data  
Clinical and anthropometric data were collected at the time of liver biopsy. Anthropometric indexes 
(height, weight, WC, and hip circumference) were measured as recommended by the WHO (21). 
According to their BMI, patients were classified as normal-weight (BMI<24.9 kg/m2), overweight 
(24.9-29.9 kg/m2) or obese (≥30 kg/m2). Laboratory evaluation included liver routine biochemistry 
(alanine aminotransferases [ALT], aspartate aminotransferases [AST], gamma-glutamyl 
transpeptidase [GGT] total bilirubin, albumin, platelet count) and metabolic parameters (glucose, 
insulin, total cholesterol, high density lipoprotein [HDL] cholesterol and triglycerides). 
The metabolic syndrome was defined according to the presence of at least three out of five 
components among waist circumference >94 cm for men and >80 for women, fasting blood glucose 
> 100mg/dL, triglycerides > 150 mg/dL or under treatment, HDL-cholesterol <40 mg/dL in men, < 
50 mg/dL in women, blood pressure >130/85 mmHg or under treatment (25). The degree of insulin 
resistance (IR) was derived from the HOMA-IR using the following formula: insulin x glucose/22.5 
(26). Blood samples were collected at the time of liver biopsy and stored at −80◦C for further 
analysis. 
 
Non-invasive prediction of NASH and fibrosis 
The newly released  Index of NASH ( ION) was calculated according to the following equation: 
1.33 waist to hip ratio +0.03 x triglycerides (mg/dL) + 0.18 x ALT (U/L) +8.53 x HOMA – 13.93 in 
men; 0.02 x triglycerides (mg/dL) + 0.24 x ALT (U/L) + 9.61 x HOMA – 13.99 in women (20).  
CK18-Asp396 apoptotic fragment determination was assessed by the commercial M30-
Apoptosense ELISA Kit (PEVIVA, Sweden) as previously described (22). Briefly, samples were 
placed into wells coated with mouse monoclonal antibody as a catcher. After washing, a horseradish 
peroxidase-conjugated antibody (M30) was used for detection. The absorption was determined with 
an ELISA reader at 450 nm using the cubic spline algorithm. Inter and intra-assay coefficient of 
variation were below 10%. The concentration of CK18-Asp396 was expressed as units per liter 
(U/L). 
The NAFLD fibrosis score and FIB-4 were calculated from published algorithms (4-8).  
Liver stiffness was measured by FibroScan (Echosens, Paris, France) within three months from 
liver biopsy by an expert operator and was expressed in kilopascals (kPa) as the median value of the 
successful determinations. Only LS values with at least 10 successful measurements (success rate 
higher than 60 % and interquartile range minor than 30) were considered reliable and used for the 
analysis. 
 
Liver Histology 
Liver biopsies were stained with hematoxylin and eosin, Masson’s trichrome, and special stains for 
iron and copper. Specimens were analyzed at each clinical center by expert liver pathologists 
blinded to patient clinical characteristics. The average size of liver biopsies was 25 mm (range 15-
45) with at least 11 portal tracts. Liver biopsies were graded and staged according to Kleiner et al. 
(15,16). The diagnosis of NASH was done according to the joint presence of steatosis, ballooning 
and lobular inflammation with or without fibrosis.  Severe fibrosis was defined according to the 
presence of F3 or F4 staging. 
 
Statistical analysis. 
Data are reported as mean and standard deviation (SD) for continuous normally distributed 
variables, as median and 95% confidence interval for the median (95% CI) for continuous non-
normally distributed variables and as frequency (%) for categorical variables. Comparisons between 
groups were performed using the Kruskal-Wallis non-parametric test. For categorical data, the 
Fisher exact test or the Chi-square test were used as appropriate.  
The diagnostic accuracy of ION and CK18-Asp396 apoptotic fragment for the diagnosis of NASH 
was derived from the Receiver Operating Characteristic (ROC) Curves according to the cut-off 
values previously described (50 and 279 U/L, respectively) (23). The same analysis was used to 
assess the ability of each non-invasive score and their combinations to exclude severe fibrosis 
(F3/F4). We also assessed for the first time the diagnostic accuracy of ION and CK18-Asp396 
apoptotic fragment for the prediction of fibrosis. The best cut-offs were derived from the Youden 
index. Cut-off values for LS, NFS and Fib4 were derived from the literature (4,6,24). Sensitivity 
(Se), specificity (Sp), positive likelihood ratio (LR+), negative likelihood ratio (LR-), positive 
predictive value (PPV), negative predictive value (NPV) and the rate of correctly identified cases 
were calculated accordingly for each index or combination. Values of p < 0.05 were considered 
statistically significant. All the analysis were performed with MedCalc Software version 12 
(Mariakerke, Belgium).  
 
Results 
Clinical, biochemical and histological features of the study subjects 
The anthropometric, biochemical and histological data of the study subjects are reported in Table 1. 
Overall, MetS was diagnosed in approximately 32%  and T2DM in 20% of the patients enrolled. 
When grouped according to center, visceral obesity was more prevalent in the Southern cohort 
(73.4% vs 67.5%, p=0.0102, respectively) while hypertension in the Northern one (23.7 vs 35%, 
p=0.0267). In the Northern cohort a larger proportion of subjects were lean (21.1% vs 11.8% in the 
Southern cohort), but the prevalence of the PNPLA3 rs738409 C>G polymorphism was similar 
(PNPLA3 CG 48.9% vs  49.4% and PNPLA3 GG 23.3% vs 21.3% in the Northern vs Southern 
cohort, respectively: p=ns for both). In the whole cohort, obesity was found in 40% of cases, half 
than in the original validation cohort of the ION index, where 95% of subjects were obese. When 
we subdivided the study subjects according to BMI < or ≥ 30 (Table 2), liver function tests were 
similar in the two groups but obese patients had a more severe liver damage, including a higher 
prevalence of NASH. All the non-invasive biomarkers, including ION, and LS were significantly 
higher in obese compared to non-obese subjects.  
 
Non-invasive prediction of Non-Alcoholic Steatohepatitis 
The average value of ION and of serum CK18-Asp396 apoptotic fragment levels in patients with 
Simple fatty Liver (SFL) and NASH are reported in Figure 1. Both ION and CK18-Asp396 were 
significantly higher in patients with histological diagnosis of NASH, although the broad range of 
CK18-Asp396 values confirmed its limited clinical usefulness.  In our NAFLD population the 
diagnostic accuracy of ION for the identification of NASH was less satisfactory than what reported 
by Otgonsuren et al (20), with an AUROC = 0.687 (95% CI = 0.62-0.75). While in the original 
validation cohort an ION cut-off ≥ 50 used to identify NASH from simple steatosis provided a 
sensitivity of 92 and a specificity of 60 (20), in our population the same cut-off had a poor 
sensitivity (28%) and a good specificity (92% ), with a PPV of 91% and a NPV of 30%. Since ION 
was tested in morbid obese patients, we calculated a new cut-off value for our cohort by the Youden 
Index. Overall, the new ION cut-off (>26) significantly improved the sensitivity (73%) but 
decreased the specificity (60%) for the diagnosis of NASH, with a PPV of 84% and a NPV of 43%, 
74% of cases correctly classified (Table 3) and 17.8% of false negative cases. In order to understand 
how ION is influenced by obesity, we evaluated its diagnostic performance according to BMI (< or  
≥30). The AUROCs in the two subgroups did not differ significantly, although it was slightly better 
in the obese one (Table 3). In the obese sub-group, a cut-off > 28 correctly classified 81.5% of cases 
with a PPV of 88%, a NPV of 36% and 17% of false negative, while in non-obese subjects a cut-off 
> 29 was able to properly identify 69.9% of cases, with a PPV of 84%, a NPV of 43% and 13.8% of 
false negative cases (Table 3).  
The diagnostic accuracy of CK18-Asp396 for the identification of NASH in our NAFLD population 
was limited (AUC = 0.60, 95% CI = 0.53-0.66). Overall, the published cut-off value of 279 U/L 
provided a sensitivity of 48% and a specificity of 68% with a PPV and a NPV of 83% and 29%, 
respectively. The performance of CK18-Asp396 was unaffected by BMI (data not shown).  
At multivariable logistic regression analysis, after controlling for BMI, age, gender and center, ION 
was the only independent predictor of NASH (Table 4). However, when we re-analysed according 
to the presence/absence of obesity (BMI ≥30), ION was able to predict NASH in the obese sub-
group only (OR=4.8, 95%CI=1.1-21.1, p=0.0398; data not shown). 
 
Non-invasive exclusion of severe fibrosis 
Since the histological features of NASH are often associated with fibrosis and can predict it, we 
tested whether both ION and CK18-Asp396 were able to identify the presence and extent of 
fibrosis. The median values of ION and CK18-Asp396 in the whole population according to staging 
are shown in Fig.2. ION and CK18-Asp396 significantly increased according to the degree of 
hepatic fibrosis (Kruskal Wallis p=0.001 and p<0.0001, respectively) and were able to discriminate 
F0/1 from F2 and F3/F4 (Fig. 2). However, the overall performance of both indexes for the 
exclusion of severe fibrosis (F3/F4) was poor (AUC=0.61 for ION and AUC=0.67 for CK18-
Asp396, Supplementary Figure 1). The newly identified cut-offs > 49 for ION and > 283 U/L for 
CK18-Asp396 correctly classified 76% and 74% of cases in the whole cohort. The subdivision 
according to BMI (< or  ≥30) did not improve the results (data not shown). The performance of ION 
and CK18-Asp396 as markers of severe fibrosis was worse compared to LS, NFS and Fib4 
(Supplementary Table 1). Among all the non-invasive markers of fibrosis, only Liver stiffness 
reached an acceptable diagnostic accuracy, defined by AUC ≥0.80, in our NAFLD cohort.  
Finally, we tested whether the combination of markers of NASH and fibrosis performed better than 
two or more markers of fibrosis. The combination of LS and Fib-4 yielded the best results (AUROC 
0.878), while LS and ION or LS and NFS had a similar performance. (Supplementary Table 1). 
 
Discussion 
The non-invasive identification of NAFLD patients at high risk for advanced liver disease is the 
most important unmet need in clinical practice: it impedes the identification of subjects who may 
benefit from more intensive management and closer follow up and it significantly hampers the 
development of new drugs, currently based on the demonstration of an histological improvement.  
Given the close relationship between the progression of the metabolic disturbances and the hepatic 
damage, several non-invasive algorithms are based on clinical and biochemical components of the 
MetS. One of the newly released index for the prediction of NASH is ION, based on the 
combination of visceral obesity, triglycerides, ALT and HOMA-IR. Despite the initially promising 
results (20), in this study ION did not show an acceptable diagnostic accuracy for the diagnosis of 
NASH in an external cohort of patients with biopsy-proven NAFLD. ION has been originally 
validated in a population of morbid obese subjects, hence one of the reasons behind the failure can 
be related to the different phenotype of NAFLD in our cohort, where 60% of patients were non-
obese. The validation of ION in the obese subgroup was slightly, although not significantly, better 
than in the non-obese one, thus suggesting that ION cannot be considered an universal index and its 
reliability changes according to the phenotypic expression of NAFLD. In fact, although obesity and 
Type 2 Diabetes are classical risk factors for NASH, patients with NAFLD can have different 
combinations of MetS components with different clinical implications and prognosis: up to one 
third of our patients had arterial hypertension, which has been linked to a more severe progression 
of the disease (27).  
Another possible bias is the use of ION in patients with Type 2 Diabetes, since the use of HOMA-
IR is not recommended in T2DM. ION has been developed in the general population where 
prevalence of T2DM was around 5% in NAFLD and 0.7% in non-NAFLD (20), while in our cohort 
T2DM was present in 20% of subject. However, when we repeated the analysis without diabetic 
subjects, no difference was observed in any of the calculated parameters (data not shown). 
Our analysis further confirmed the scarce clinical usefulness of CK18, mainly due to the broad 
range of values, and highlights once again that up to date there is no reliable marker able to identify 
the presence of NASH. 
Since necroinflammation usually precedes and predicts fibrosis, we also assessed the suitability of 
the ION index as well as of CK-18 for the non-invasive detection of severe fibrosis. Once again 
ION performed better than CK-18 in excluding severe fibrosis, but the overall accuracy of ION and 
CK-18 was modest compared to that of the currently recommended tools (NFS, FIB-4 and LS) and 
did not provide any significant advantage. The combination of markers of NASH and fibrosis was 
not better than the combination of two or more markers of fibrosis. The diagnostic accuracy for 
excluding severe fibrosis was significantly improved by the association of FIB-4 and LS, while the 
combination of LS with ION or NFS was similar and less satisfactory.  
Another important observation stemming from this study is the lower performance of markers based 
on measures of obesity in non-obese subjects with NAFLD. In particular, the need of a different 
approach to lean patients with NAFLD is one of the most important issue in clinical practice, but a 
discussion about the modality is beyond the scope of this study. 
This study has some limitations. First of all, patients enrolled at tertiary care centers could be 
different from the majority of NAFLD/NASH cases in the general population. For the same reasons, 
the cut-offs we found and used to evaluate ION could be limited by the validity of the results in 
different populations and settings. Further, the accuracy of liver biopsy as gold standard to diagnose 
NASH and fibrosis can be affected by several well-known bias, including sampling errors and 
interobserver variability. As in other studies, we collected specimens of at least 15 mm of length 
and the minimum of ten complete portal tracts in order to minimize some risks. 
In conclusion, our study showed that ION is not feasible for the non-invasive diagnosis of NASH 
across different populations of NAFLD patients, mainly because its limited reproducibility in non-
obese subjects. The combination of ION with a marker of fibrosis does not significantly improve 
the diagnostic performance of the tools currently recommended (LS, FIB-4 and LS). Although the 
identification of mild and moderate fibrosis remains elusive, LS is still the best non-invasive 
technique for the exclusion of severe fibrosis and its diagnostic performance can be increased by the 
combination with FIB-4. 
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Figure legends 
 
Fig. 1. Index Of NASH values (A) and cytokeratin 18-Asp396 apoptotic fragment levels (B) 
according to the diagnosis of NASH. 
 
Fig. 2. Index of NASH values (A) and cytokeratin 18-Asp396 apoptotic fragment (B) according to 
the degree of hepatic fibrosis.  
 
Supplementary Fig. 1. Receiver Operating Characteristic (ROC) curves for the identification of 
severe fibrosis of Index of NASH (A) and cytokeratin 18-Asp396 apoptotic fragment (B). 
 
 
 
 
 
Table 1. Clinical, biochemical and histological characteristics of the patients population according 
to the enrollment centre  (Southern cohort, N=169 and Northern cohort, N=223). 
 Total 
(N=292) 
Southern cohort 
(N=169) 
Northern cohort 
(N=123) 
P 
Age, years 44.7 ± 12.8 45.3 ± 13.4 44.5 ± 12.4 0.6187 
BMI, kg/m2 28.9 ± 4.1 29.3 ± 4.1 28.4 ± 3.9 0.0448 
Sex, M/F (%) 201/91 (68.8/31.2) 113/56 (66.9/33.1) 88/35 (71.5/28.5) 0.4686 
Normal weight 
/overweight/obese, n      (%) 
46/130/116 
(15.8/44.5/39.7) 
20/79/70 
(11.8/46.8/41.4) 
26/51/46 
(21.1/41.5/37.4) 
 
Waist, cm 99 ± 11 100 ± 12 97 ± 10 0.0347 
Hip, cm 104 ± 8 103 ± 8 105 ± 8 0.0220 
MS, n (%) 93 (31.8) 50 (29.6) 43 (35) 0.7315 
T2DM, n (%) 57 (19.5) 32 (18.9) 25 (20.3) 0.9725 
AST, IU/L 36 (35-38) 36 (35-40) 36 (33-40) 0.4578 
ALT, IU/L 66 (61-71) 67 (59-73) 64 (56-73) 0.4083 
gGT, IU/L 61 (53-68) 58 (49-68) 65 (54-78) 0.3445 
BT, mg/dL 0.77 ± 0.72 0.68 ± 0.03 0.91 ± 1.02 0.0197 
PLT, 109/L 219 (213-227) 217 (209-228) 222 (213-232) 0.6040 
Fasting glucose, mg/dL 93 (90-95) 93 (89-96) 93 (90-96) 0.2779 
Fasting insulin, mIU/mL 12.8 (12-14) 14 (12.8-15) 12 (10.3-12.7) 0.0292 
HOMA-IR 2.9 (2.75-3.11) 3.1 (2.8-3.5) 2.7 (2.3-3) 0.0337 
Total-cholesterol, mg/dL 203 (196-207) 203 (196-211) 200 (184-207) 0.1769 
HDL-cholesterol, mg/dL 48 (46-49) 47 (45-50) 48 (46-50) 0.9741 
TG, mg/dL 129 (121-140) 133 (122-146) 122 (112-144) 0.7690 
LS, kPa 7.1 (6.5-7.7) 6.8 (6.1-7.6) 7.6 (6.6-8.5) 0.0981 
CK18-Asp396, U/L 235 (217-255) 252 (242-303) 198 (173-228) 0.0006 
ION 32 (29-34) 32 (29-37) 30 (27-35) 0.1508 
NFS -2.341 ± 1.552 -2.296 ± 1.552 -2.406 ± 1.556 0.7984 
Fib4 0.89 (0.84-0.96) 0.92 (0.85-1.04) 0.86 (0.8-0.96) 0.2970 
Histological features     
Steatosis, n (%) 
            1 
            2 
            3 
 
126 (43.2) 
95 (32.5) 
71 (24.3) 
 
59 (34.9) 
60 (35.5) 
50 (29.6) 
 
67 (54.5) 
35 (28.4) 
21 (17.1) 
0.0004 
Ballooning, n (%) 
            0 
 
34 (11.6) 
 
13 (7.7) 
 
21 (17.1) 
0.0020 
            1 
            2            
124 (42.5) 
134 (45.9) 
69 (40.8) 
87 (51.5) 
55 (44.7) 
47 (38.2) 
Lobular inflammation, n (%) 
            0 
            1 
            2 
            3 
 
40 (13.7) 
165 (56.5) 
80 (27.4) 
7 (2.4) 
 
12 (7.1) 
83 (49.1) 
68 (40.2) 
6 (3.6) 
 
28 (22.8) 
82 (66.7) 
12 (9.7) 
1 (0.8) 
<0.0001 
NAS, n (%) 
            1-2 
            3-4 
            ≥ 5 
 
38 (13) 
122 (41.8) 
132 (45.2) 
 
17 (10) 
50 (29.6) 
102 (60.4) 
 
21 (17.1) 
72 (58.5) 
30 (24.4) 
<0.0001 
Fibrosis, n (%) 
            0 
            1 
            2 
            3 
            4 
 
77 (26.4) 
67 (22.9) 
75 (25.7) 
53 (18.2) 
20 (6.8) 
 
37 (21.9) 
45 (26.6) 
52 (30.8) 
26 (15.4) 
9 (5.3) 
 
40 (32.5) 
22 (17.9) 
23 (18.7) 
27 (22) 
11 (8.9) 
0.9303 
NASH, n (%) 224 (76.7) 146 (86.4) 78 (63.4) <0.0001 
 
Data are reported as mean ± standard deviation for normal continues variables, as median (95% confidence 
interval for the median) for continues non-normal variables and as frequency (%) for categorical variables. 
ALT, aspartate aminotransferases; AST, aspartate aminotransferases; BMI, body mass index; BT, total 
bilirubin; CK18-Asp396, cytokeratin 18-Aspartate 396 apoptotic fragment; gGT, gamma-glutamyl 
aminotransferases; HDL, high density lipoprotein; HOMA, homeostasis model of assessment; ION, index of 
non-alcoholic steatohepatitis; IR, insulin resistance; LS, liver stiffness; MS, metabolic syndrome; NASH, 
non-alcoholic steatohepatitis; NFS, non-alcoholic fatty liver disease fibrosis score; PLT, platelets; TG, 
triglycerides; T2DM, type 2 diabetes mellitus.  
Table 2. Clinical, biochemical and histological characteristics of the patients population according 
to the presence of obesity (OB)  (Non-Obese, N=176 and Obese, N=116). 
 Non-OB 
(N=176) 
OB 
(N=116) 
P 
Age, years 43.7 ± 13.1 46.9 ± 12.6 0.0378 
Sex, M/F (%) 127/49 (72.2/27.8) 74/42 (63.8/36.2) 0.1672 
AST, IU/L 36 (33-38) 38 (35-43) 0.0662 
ALT, IU/L 69 (58-73) 65 (59-74) 0.5870 
gGT, IU/L 61 (49-75) 61 (54-70) 0.4837 
HOMA-IR 3.03 ± 2.42 5.00 ± 3.4 <0.0001 
LS, kPa 6.1 (5.9-6.6) 8.8 (8.0-9.9) <0.0001 
CK18-Asp396, U/L 208 (186-243) 266 (235-316) 0.0003 
ION 28 (26-32) 35 (32-43) 0.0038 
NFS -2.701 ± 1.370 -1.795 ± 1.655 <0.0001 
Fib4 1.06 ± 0.78 1.32 ± 0.92 0.0108 
Histological features    
Steatosis, n (%) 
            1 
            2 
            3 
 
89 (50.6) 
56 (31.8) 
31 (17.6) 
 
37 (31.9) 
39 (33.6) 
40 (34.5) 
0.0002 
Ballooning, n (%) 
            0 
            1 
            2            
 
25 (14.2) 
82 (46.6) 
69 (39.2) 
 
9 (7.8) 
42 (36.2) 
65 (56.0) 
0.0040 
Lobular inflammation, n (%) 
            0 
            1 
            2 
            3 
 
31 (17.6) 
101 (57.4) 
40 (22.7) 
4 (2.3) 
 
9 (7.7) 
64 (55.2) 
40 (34.5) 
3 (2.6) 
0.0068 
NAS, n (%) 
            1-2 
            3-4 
            ≥ 5 
 
32 (18.2) 
80 (45.4) 
64 (36.4) 
 
6 (5.2) 
42 (36.2) 
68 (58.6) 
<0.0001 
Fibrosis, n (%) 
            0 
            1 
 
60 (34.1) 
48 (27.3) 
 
17 (14.7) 
19 (16.4) 
<0.0001 
            2 
            3 
            4 
40 (22.7) 
20 (11.4) 
8 (4.5) 
35 (30.2) 
33 (28.4) 
12 (10.3) 
NASH, n (%) 126 (71.6) 98 (84.5) 0.0160 
 
Data are reported as mean ± standard deviation for normal continues variables, as median (95% confidence 
interval for the median) for continues non-normal variables and as frequency (%) for categorical variables. 
ALT, aspartate aminotransferases; AST, aspartate aminotransferases; CK18-Asp396, cytokeratin 18-
Aspartate 396 apoptotic fragment; gGT, gamma-glutamyl aminotransferases; HDL, high density lipoprotein; 
HOMA, homeostasis model of assessment; ION, index of non-alcoholic steatohepatitis; IR, insulin 
resistance; LS, liver stiffness; NASH, non-alcoholic steatohepatitis; NFS, non-alcoholic fatty liver disease 
fibrosis score; OB, obese; PLT, platelets.  
Table 3. Area under the curve, sensitivity, specificity, positive predictive value, negative predictive 
value and accuracy of ION for the diagnosis of NASH according to the presence of obesity (OB). 
ION 
AUC 
(95% CI) 
Cut-off 
Se 
(%) 
Sp 
(%) 
PPV 
(%) 
NPV 
(%) 
Cases correctly 
classified 
        
All subjects 0.687 (0.62-0.75) > 26 73 60 84 43 74.5 % 
Non-OB  
(BMI < 30 kg/m2) 
0.663 (058-074) > 29 57 74 84 43 69.9 % 
OB  
(BMI ≥ 30 kg/m2) 
0.700 (0.59-0.79) > 28 79 53 88 36 81.5 % 
 
AUC, area under the receiver operating characteristic curve; BMI, body mass index; CI, confidence interval; 
ION, index of non-alcoholic steatohepatitis; NPV, negative predictive value; OB, obese; PPV, positive 
predictive value; Se, sensitivity, Sp, specificity.  
Table 4. Univariate and multivariable logistic regression analysis of Index of NASH and 
cytokeratin 18-Asp396 for the diagnosis of NASH. 
 All subjects (N=292) 
 Univariate analysis Multivariable analysis 
 OR (95% CI) P OR (95% CI) P 
Age, y 1.0 (0.9-1.0) 0.5347 0.99 (0.96-1.0) 0.4100 
Sex, M  0.3 (0.2-0.7) 0.0031 0.4 (0.1-0.9) 0.0395 
BMI, kg/m2 1.2 (1.1-1.2) 0.0002 1.2 (1.0-1.3) 0.0080 
Southern Center 3.7 (2.1-6.5) < 0.0001 6.3 (2.7-14.5) < 0.0001 
ION > 26 3.9 (2.1-7.1) < 0.0001 2.6 (1.2-5.7) 0.0156 
CK18-Asp396 ≥ 279 1.6 (0.8-3.1) 0.1447 0.6 (0.3-1.4) 0.2471 
 
BMI, body mass index; CI, confidence interval; CK18-Asp396, cytokeratin 18 aspartate 396 apoptotic 
fragment; ION, index of non-alcoholic steatohepatitis; M, male gender; OR, odd ratio;  y; years 
